Layoffs are hitting Sanofi-Aventis and possibly Astra-Zeneca and Eli Lilly, says Derek Lowe at In the Pipeline. He says that Astra-Zeneca's cuts may be "follow-through from their earlier nonspecific announcements - it looks as if they're finally going to start getting down to some details" and that at Lilly, some chemistry positions may be lost. Ed Silverman at Pharmalot adds that the Sanofi-Aventis cuts are coming in "dribs and drabs" and recently have included 70 people in medical affairs at its Bridgewater, NJ offices.